1. Home
  2. MEC vs CTNM Comparison

MEC vs CTNM Comparison

Compare MEC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mayville Engineering Company Inc.

MEC

Mayville Engineering Company Inc.

HOLD

Current Price

$21.64

Market Cap

435.4M

Sector

Industrials

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.39

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEC
CTNM
Founded
1945
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
435.4M
480.5M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
MEC
CTNM
Price
$21.64
$12.39
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$24.33
$19.00
AVG Volume (30 Days)
106.0K
248.6K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.65
N/A
Revenue Next Year
$8.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.99
$3.35
52 Week High
$22.37
$16.33

Technical Indicators

Market Signals
Indicator
MEC
CTNM
Relative Strength Index (RSI) 67.32 39.90
Support Level $17.20 $11.54
Resistance Level $22.37 $13.26
Average True Range (ATR) 0.89 0.62
MACD 0.22 -0.03
Stochastic Oscillator 98.68 20.27

Price Performance

Historical Comparison
MEC
CTNM

About MEC Mayville Engineering Company Inc.

Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: